The impact of 10-valent Pneumococcal Conjugate Vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children

Micah Silaba, Michael Ooko, Christian Bottomley, Joyce Sande, Rachel Benamore, Kate Park, James Ignas, Kathryn Maitland, Neema Mturi, Anne Makumi, Mark Otiende, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Tahreni Bwanaali, Evasius Bauni, Fergus Gleeson, Maria Deloria Knoll, Ifedayo Adetifa, Kevin MarshThomas N. Williams, Tatu Kamau, Shahnaaz Sharif, Orin S. Levine, Laura L. Hammitt, J. Anthony G. Scott

Research output: Contribution to journalArticlepeer-review


Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes but the burden of pneumococcal disease in developing countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the impact of PCV on pneumonia incidence. Methods We linked prospective hospital surveillance for clinically-defined WHO severe or very-severe pneumonia at Kilifi County Hospital from 2002-2015 to population surveillance at Kilifi Health and Demographic Surveillance System, comprising 45,000 children aged <5 years. Chest radiographs were read according to a WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in January 2011. In Kilifi, there was a catch-up campaign for children aged <5 years. We estimated the impact of PCV10 on pneumonia incidence through interrupted time series analysis accounting for seasonal and temporal trends. Findings The incidence of admission with clinically-defined pneumonia in 2002/3 was 21·7/1000/year in children aged 2-59 months. This declined progressively over 13 years. By the end of March 2011, 61·1% of children aged 2-11 months received ≥2 doses and 62·3% of children aged 12-59 months received ≥1 dose of PCV10. Adjusted incidence rate ratios for admissions with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition), associated with PCV10 introduction, were 0·52 (95% CI 0·32-0·86), 0·73 (95% CI 0·54-0·97) and 0·63, (95% CI 0·31-1·26), respectively. The annual incidence of clinically-defined pneumonia in December 2010 was 12·2/1000; this was reduced by 3·3/1000 with PCV10 introduction. Interpretation Over 13 years, hospitalisations for clinically-defined pneumonia declined progressively at Kilifi County Hospital but fell abruptly by 27% in association with PCV10 introduction. The incidence of radiologically-confirmed pneumonia fell by 48%. The burden of childhood pneumonia in Kilifi, Kenya, has been reduced substantially by PCV10. Funding Gavi, Wellcome Trust

Original languageEnglish (US)
JournalUnknown Journal
StatePublished - Jul 18 2018

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'The impact of 10-valent Pneumococcal Conjugate Vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children'. Together they form a unique fingerprint.

Cite this